share_log

Tempus AI | 8-K: Current report

Tempus AI | 8-K: Current report

Tempus AI | 8-K：重大事件
美股SEC公告 ·  2024/11/06 05:06

Moomoo AI 已提取核心信息

Tempus AI has entered into a Securities Purchase Agreement to acquire Ambry Genetics Corporation from REALM IDx for $375 million in cash and 4.84 million shares of Class A common stock. Ambry Genetics is a leader in genetic testing focused on understanding genetics-disease relationships. The deal includes a one-year lock-up period for approximately 2.15 million shares of the stock consideration.To finance the acquisition, Tempus has secured commitments from Ares Capital Corporation for a $100 million senior secured revolving credit facility and $200 million in additional term loans. The transaction includes customary representations, warranties, and covenants, with $5 million of the cash consideration held in escrow for post-closing adjustments.The acquisition is expected to close in Q1 2025, subject to regulatory approvals including Hart-Scott-Rodino Act clearance and other customary closing conditions. The agreement includes a termination date of May 4, 2025, which can be extended by three months if regulatory approvals are pending.
Tempus AI has entered into a Securities Purchase Agreement to acquire Ambry Genetics Corporation from REALM IDx for $375 million in cash and 4.84 million shares of Class A common stock. Ambry Genetics is a leader in genetic testing focused on understanding genetics-disease relationships. The deal includes a one-year lock-up period for approximately 2.15 million shares of the stock consideration.To finance the acquisition, Tempus has secured commitments from Ares Capital Corporation for a $100 million senior secured revolving credit facility and $200 million in additional term loans. The transaction includes customary representations, warranties, and covenants, with $5 million of the cash consideration held in escrow for post-closing adjustments.The acquisition is expected to close in Q1 2025, subject to regulatory approvals including Hart-Scott-Rodino Act clearance and other customary closing conditions. The agreement includes a termination date of May 4, 2025, which can be extended by three months if regulatory approvals are pending.
Tempus人工智能已签署证券购买协议，以现金37500万美元和484万股A类普通股从REALm IDx收购Ambry Genetics Corporation。Ambry Genetics在基因检测领域处于领先地位，专注于理解基因与疾病之间的关系。交易包括对约215万股股票对价的一年锁定期。为了融资收购，Tempus已获得Ares Capital Corporation的承诺，提供10000万美元的高级担保循环信贷额度和20000万美元的额外定期贷款。该交易包含常规的陈述、保证和契约，500万美元的现金对价将保留在托管账户中，以便进行交割后的调整。收购预计将在2025年第一季度完成，具体取决于包括Hart-Scott-Rodino法案清除及其他常规交割条件在内的监管批准。协议包括一个终止日期，即2025年5月4日，如果监管批准仍在进行中，可以延长三个月。
Tempus人工智能已签署证券购买协议，以现金37500万美元和484万股A类普通股从REALm IDx收购Ambry Genetics Corporation。Ambry Genetics在基因检测领域处于领先地位，专注于理解基因与疾病之间的关系。交易包括对约215万股股票对价的一年锁定期。为了融资收购，Tempus已获得Ares Capital Corporation的承诺，提供10000万美元的高级担保循环信贷额度和20000万美元的额外定期贷款。该交易包含常规的陈述、保证和契约，500万美元的现金对价将保留在托管账户中，以便进行交割后的调整。收购预计将在2025年第一季度完成，具体取决于包括Hart-Scott-Rodino法案清除及其他常规交割条件在内的监管批准。协议包括一个终止日期，即2025年5月4日，如果监管批准仍在进行中，可以延长三个月。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Aclarion
    ACON
    -- 0.0670
    Streamline Health Solutions
    STRM
    -- 4.366
    OneMedNet
    ONMD
    -- 1.410
    新氧
    SY
    -- 0.950
    FOXO Technologies
    FOXO
    -- 0.2796
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。
    热门讨论
    特斯拉财报在即：股价能否继续攀升？
    🎙️讨论： 1. 面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 2. 特斯拉将在1月29日盘后公布财报，你认为会超出市场预期吗？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！